A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Placebo in Binge Eating Disorder, sponsored by Shire. Completed at 50 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.
Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 10th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 31st registered.
233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.
Browse Binge-Eating Disorder studies →20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:
Lindner Center of HOPE · Sites in United States
Ages up to 18
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
University of Oklahoma · Sites in United States
Ages 18–120
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 25 · Phase 4 3
First in 1994; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 383 is above the median of 77 across 190 interventional studies indexed under Binge-Eating Disorder.
Median enrollment 67 across the 112 interventional studies, 224 across the 8 observational. Of the 89 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 122 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 6 studies filed under Binge-Eating Disorder — fewer than ten, so there is no comparison to draw.
12 of the studies in Binge-Eating Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413433Phase 3Axsome Therapeutics, Inc.Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | 2026-12 |
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06485687Ali RezaiLow Intensity Focused Ultrasound for Binge Eating Disorder | 2026-12-31 |
| NCT05664516Massachusetts General HospitalA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder | 2027-01 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 122 studies in Binge-Eating Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject meets the following criteria for a diagnosis of BED:
Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).
The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.
Marked distress regarding binge eating. The binge eating occurs, on average, at least 2 days a week for 6 months. The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.
Exclusion Criteria-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489 (Lisdexamfetamine dimesylate)
Drug: Placebo
50 or 70 mg administered orally, once-daily for up to 12 weeks
Also known as: Vyvanse, Venvanse, LDX
Administered once-daily, orally, for up to 12 weeks
Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)
Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on participant binge diary.
Time frame: Baseline and Visit 8 (Weeks 11-12)
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: Up to 12 weeks
Percentage of Participants With a 4-Week Cessation From Binge Eating
4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.
Time frame: Up to 12 weeks
Percent Change From Baseline in Body Weight at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12
The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks
Time frame: Baseline and Week 12/Early termination (ET)
Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks
Time frame: Baseline and Week 12/ET
Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks
Time frame: Baseline and Week 12/ET
Binge Eating Response
Response is based on the reduction in the number of binge eating episodes. Percentage of participants with response was reported. Responses were categorized as follows: 1-week Cessation = 100% reduction in binge episodes during the preceding 7 days. Marked Reduction = 99% to 75% reduction during the time since the previous visit. Moderate Reduction = 74% to 50% reduction during the time since the previous visit. Negative to Minimal Reduction = \<50% reduction during the time since the previous visit.
Time frame: Week 12/ET
Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12)
Time frame: Baseline and Visit 8 (Weeks 11-12)
Change From Baseline in Eating Inventory Scores at Week 12
The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior. There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.
Time frame: Baseline and Week 12
Change From Baseline in Binge Eating Scale (BES) Score at Week 12
The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a participant has greater control over eating behavior and 4 denoting that a participant had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.
Time frame: Baseline and Week 12
Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12
The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Participants were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.
Time frame: Baseline and Week 12
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Mobility
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various mobility conditions were reported.
Time frame: Up to 12 weeks
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Self-Care
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various self-care conditions were reported.
Time frame: Up to 12 weeks
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Usual Activities
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various usual activities conditions were reported.
Time frame: Up to 12 weeks
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Pain/Discomfort
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various pain/discomfort conditions were reported.
Time frame: Up to 12 weeks
EuroQoL Group 5-Dimension 5-Level Self-Report (EQ-5D-5L): Anxiety/Depression
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various anxiety/depression conditions were reported.
Time frame: Up to 12 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Number of participants with suicidal ideation and suicidal behavior were reported.
Time frame: Up to 12 weeks
Amphetamine Cessation Symptom Assessment (ACSA) Total Score
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: Up to 12 weeks
Participants were recruited between 12-Nov-2012 and 19-June-2013 and locations included medical clinics \& research centers.
| Milestone | PLACEBO | SPD489 |
|---|---|---|
| Started | 191 | 192 |
| Treated | 187 | 192 |
| Completed | 157 | 158 |
| Not completed | 34 | 34 |
| Withdrew: Withdrawal by subject | 14 | 12 |
| Withdrew: Adverse event | 5 | 12 |
| Withdrew: Lost to follow-up | 8 | 3 |
| Withdrew: Protocol violation | 4 | 2 |
| Withdrew: Other | 1 | 4 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
Binge days defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on participant binge diary.
| Binge days per week | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12) | -2.51 ± 0.125 | -3.87 ± 0.124 |
CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores | 47.3 (40.1 to 54.5) | 82.1 (76.7 to 87.6) |
4-week cessation from binge eating is defined as no binge eating episodes for 28 consecutive days prior to the last study visit.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| Percentage of Participants With a 4-Week Cessation From Binge Eating | 14.1 (9.1 to 19.2) | 40.0 (33.0 to 47.0) |
| percent change | PLACEBO | SPD489 |
|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 | 0.11 ± 0.295 | -6.25 ± 0.292 |
The Y-BOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. Reduction in total score indicates improvement.
| units on a scale | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Total Score at Week 12 | -8.28 ± 0.550 | -15.68 ± 0.546 |
| millimole per liter (mmol/L) | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in Fasting Triglyceride Levels at Up to 12 Weeks | 0.122 ± 0.0405 | -0.077 ± 0.0393 |
| mmol/L | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline In Fasting Total Cholesterol Levels at Up to 12 Weeks | -0.094 ± 0.0435 | -0.305 ± 0.0422 |
| Percent hemoglobin | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in Hemoglobin A1c Levels at Up to 12 Weeks | 0.01 ± 0.016 | -0.02 ± 0.015 |
Response is based on the reduction in the number of binge eating episodes. Percentage of participants with response was reported. Responses were categorized as follows: 1-week Cessation = 100% reduction in binge episodes during the preceding 7 days. Marked Reduction = 99% to 75% reduction during the time since the previous visit. Moderate Reduction = 74% to 50% reduction during the time since the previous visit. Negative to Minimal Reduction = \<50% reduction during the time since the previous visit.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| 1-week cessation | 26.6 | 47.1 |
| Marked Reduction | 15.2 | 31.6 |
| Moderate Reduction | 17.9 | 11.8 |
| Negative to Minimal Reduction | 40.2 | 9.6 |
| Binge episodes per week | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in the Number of Binge Episodes Per Week at Visit 8 (Weeks 11-12) | -3.49 ± 0.170 | -5.27 ± 0.168 |
The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior. There are 36 true/false items, 14 items on a 4-point Likert scale (1=eat rarely to 4=always), and 1 item on a 6-point Likert scale (1=eat whatever you want to 6=constantly limiting food intake). Cognitive Restraint score ranges from 0-21. Hunger score ranges from 0-14. Disinhibition score ranges from 0-16. Higher scores denote higher levels of restrained eating, disinhibited eating and predisposition to hunger.
| units on a scale | PLACEBO | SPD489 |
|---|---|---|
| Cognitive Restraint of Eating | 1.63 ± 0.331 | 3.27 ± 0.329 |
| Disinhibition of Eating | -2.12 ± 0.286 | -6.31 ± 0.285 |
| Perceived Hunger | -1.90 ± 0.286 | -6.60 ± 0.285 |
The BES is a self-reported questionnaire containing 16 items designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. Each item is assessed based on 1 of 4 responses, with 1 denoting that a participant has greater control over eating behavior and 4 denoting that a participant had less control over eating behavior. A total score (sum of the 16 items) may range from 16-64. A lower score indicates greater control over eating behavior.
| units on a scale | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in Binge Eating Scale (BES) Score at Week 12 | -8.55 ± 0.763 | -18.87 ± 0.755 |
The FrSBe is a 46-item self-rating scale designed to measure the neurobehavioral traits associated with the 3 primary regions of the prefrontal cortex. Participants were asked to indicate the frequency with which they have engaged in certain behaviors using a rating scale from "1" (almost never) to "5" (almost always). Summary scores were calculated and converted to t-score. A decrease from baseline in FrSBe total score represents improvement.
| t-scores | PLACEBO | SPD489 |
|---|---|---|
| Change From Baseline in Frontal Systems Behavior (FrSBe) Total Score at Week 12 | -3.09 ± 0.592 | -3.40 ± 0.572 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various mobility conditions were reported.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| No problems walking about | 82.6 | 87.2 |
| Slight problems walking about | 14.0 | 10.7 |
| Moderate problems walking about | 2.8 | 2.1 |
| Severe problems walking about | 0.6 | 0 |
| Unable to walk about | 0 | 0 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various self-care conditions were reported.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| No problems washing or dressing | 89.3 | 95.7 |
| Slight problems washing or dressing | 6.7 | 3.2 |
| Moderate problems washing or dressing | 3.9 | 1.1 |
| Severe problems washing or dressing | 0 | 0 |
| Unable to wash or dress | 0 | 0 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various usual activities conditions were reported.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| No problems doing usual activities | 78.0 | 87.1 |
| Slight problems doing usual activities | 14.7 | 9.7 |
| Moderate problems doing usual activities | 6.2 | 3.2 |
| Severe problems doing usual activities | 1.1 | 0 |
| Unable to do usual activities | 0 | 0 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various pain/discomfort conditions were reported.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| No pain or discomfort | 64.6 | 71.1 |
| Slight pain or discomfort | 27.5 | 20.9 |
| Moderate pain or discomfort | 7.3 | 7.5 |
| Severe pain or discomfort | 0.6 | 0.5 |
| Extreme pain or discomfort | 0 | 0 |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Percentage of participants with various anxiety/depression conditions were reported.
| percentage of participants | PLACEBO | SPD489 |
|---|---|---|
| Not anxious or depressed | 70.2 | 72.2 |
| Slightly anxious or depressed | 19.7 | 16.6 |
| Moderately anxious or depressed | 7.9 | 9.1 |
| Severely anxious or depressed | 2.2 | 1.6 |
| Extremely anxious or depressed | 0 | 0.5 |
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Number of participants with suicidal ideation and suicidal behavior were reported.
| participants | PLACEBO | SPD489 |
|---|---|---|
| Suicidal Ideation | 3 | 2 |
| Suicidal behavior | 0 | 0 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| units on a scale | PLACEBO | SPD489 |
|---|---|---|
| Amphetamine Cessation Symptom Assessment (ACSA) Total Score | 7.3 ± 7.74 | 5.7 ± 7.37 |
Collected over From first dose of study drug up to 3 days after the last dose at up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PLACEBO | — | 2/187 (1.1%) | 67/187 (35.8%) |
| SPD489 | — | 3/192 (1.6%) | 125/192 (65.1%) |
| Event | PLACEBO | SPD489 |
|---|---|---|
| SyncopeNervous system disorders | 0/187 | 2/192 |
| Anaphylactic reactionImmune system disorders | 1/187 | 0/192 |
| Conversion disorderPsychiatric disorders | 1/187 | 0/192 |
| CholecystitisHepatobiliary disorders | 0/187 | 1/192 |
| Event | PLACEBO | SPD489 |
|---|---|---|
| Dry mouthGastrointestinal disorders | 16/187 | 76/192 |
| InsomniaPsychiatric disorders | 14/187 | 34/192 |
| HeadacheNervous system disorders | 17/187 | 26/192 |
| Decreased appetiteMetabolism and nutrition disorders | 6/187 | 17/192 |
| NauseaGastrointestinal disorders | 14/187 | 16/192 |
| IrritabilityGeneral disorders | 13/187 | 16/192 |
| Heart rate increasedInvestigations | 5/187 | 14/192 |
| AnxietyPsychiatric disorders | 2/187 | 13/192 |
| Upper respiratory tract infectionInfections and infestations | 11/187 | 8/192 |
| ConstipationGastrointestinal disorders | 4/187 | 11/192 |
Safety Analysis Set was used for Baseline Measures. The Safety Analysis Set was defined as all randomized participants who took at least 1 dose of investigational product and who had at least 1 post-baseline safety assessment completed. Four participants did not receive investigational product, therefore n=379.
| Age, Continuous(Years) | PLACEBO | SPD489 | Total |
|---|---|---|---|
| Mean | 37.6 ± 10.21 | 38.5 ± 10.4 | 38.1 ± 10.3 |
| Age, Customized(Participants) | PLACEBO | SPD489 | Total |
|---|---|---|---|
| <40 years | 102 | 98 | 200 |
| >=40 years | 85 | 94 | 179 |
| Sex: Female, Male(Participants) | PLACEBO | SPD489 | Total |
|---|---|---|---|
| Female | 163 | 165 | 328 |
| Male | 24 | 27 | 51 |
| Region of Enrollment(Participants) | PLACEBO | SPD489 | Total |
|---|---|---|---|
| GERMANY | 2 | 1 | 3 |
| SPAIN | 5 | 5 | 10 |
| SWEDEN | 15 | 13 | 28 |
| UNITED STATES | 165 | 173 | 338 |
Ran from Nov 2012 to primary completion in Sep 2013, 9 months.
Results were first posted in Jul 2014, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine